Home » Newsletters » BioWorld Science

BioWorld Science

Feb. 7, 2011

View Archived Issues

PCI-27483/gemcitabine combination is safe in advanced/metastatic pancreatic cancer

French scientists describe novel piperidine derivatives

Cancer-targeting nanoparticle-size Cornell dots to enter first-in-human trial

Bharat Biotech initiates phase III trial of thrombolytic agent THR-100 in India

Bryostatin 1 prevents synapse loss in vivo, improving symptoms of AD

Preclinical findings support role of N-acetylcysteine in TTP therapy

Armed oncolytic virus OBP-702 active against osteosarcoma cells

New drug discovery strategy creates synthetic analogues based on natural products

Derma Sciences reports phase II data on DSC-127 in diabetes-related foot ulcers

Kythera Biopharma reports phase IIb data on ATX-101

Galapagos and Merck & Co. agree to end strategic alliances

CardioVascular BioTherapeutics files for FDA fast track status for CVBT-141B

Tacere Therapeutics achieves milestone under collaboration with Pfizer

FDA sets new PDUFA date for AstraZeneca's Brilinta

Ceregene advances phase IIb CERE-120 trial in Parkinson's disease

Natural marine product largazole has osteogenic potential

Paclitaxel shows promise as treatment of spinal cord injury

FluEnz approved in E.U. for prevention of seasonal flu in children

SHELTER trial data reported on resminostat in sorafenib-resistant hepatocellular carcinoma

Lilly and JDRF to study beta-cell regeneration to treat type 1 diabetes

Anacor Pharma begins phase IIb trial of AN-2728 in psoriasis

AstraZeneca discontinues ENTHUSE Study 15 of zibotentan in prostate cancer

Aveo's anticancer antibody AV-299 to be called ficlatuzumab

Phase IIb trial of EpiCept NP-1 in chemotherapy-induced peripheral neuropathy meets primary endpoint

FDA removes clinical hold on Icagen's IND for epilepsy candidate ICA-10566

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 21, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Jan. 21, 2026.
Cell/gene therapy sector now sustainable; China competition mounting
BioWorld
There was an upbeat message for cell and gene therapy companies in the 2026 industry update presented as the J.P. Morgan Healthcare Conference opened on Monday,...
Abbvie snags PD-1/VEGF bispecific in potential $5B Remegen deal
BioWorld
With rumors regarding a couple of potential mega-mergers making the rounds, the week of the annual J.P. Morgan Healthcare Conference kicked off with the official...
Neurotrimin unveiled as marker in intellectual disability
BioWorld Science
Neurotrimin (NTM) is a member of the IgLON family, the disruption of which has been tied to emotional learning deficits and anxiety-like behavior in animal...